08037 CH BIOTECH SER
- 0.350
- -0.020-5.41%
CH BIOTECH SER News
China Biotechnology Services (08037.HK) intends to appoint Guo Yuantao as an independent non-executive director
Gelonghui, May 13 | China Biotechnology Service (08037.HK) announced that since He Junjie plans to spend more time on other business and personal matters, Dr. Ho will retire as an independent non-executive director of the company and a member of the Audit Committee, Nomination Committee and Remuneration Committee starting at the end of the company's next annual general meeting of shareholders. The board of directors has proposed the election and appointment of Guo Yuantao as an independent non-executive director. The relevant ordinary resolution will be submitted at the Annual General Meeting of Shareholders for shareholders' consideration and approval. If the proposal is approved for appointment at the Annual General Meeting of Shareholders, Guo Yuantao will act as an independent partner
Shanghai Longyao, a subsidiary of China Biotechnology Service (08037), was recognized as a specialized, special and new small and medium-sized enterprise in Shanghai in 2024
China Biotechnology Service (08037) announced that Shanghai Longyao Biotechnology Co., Ltd., an indirect non-wholly-owned subsidiary of the company...
China Biotech Services (08037.HK) placement of convertible bonds lapses
Gelonghui, April 30, 丨 China Biotechnology Service (08037.HK) announced that due to recent market conditions, placement agents have not successfully placed convertible bonds as of April 30, 2024 (the final deadline). As a result, the placement agreement did not become unconditional and expired on April 30, 2024. According to the placement agreement, all obligations and liabilities of the placement agent and the company under this agreement shall cease and end, and the parties to this agreement shall not file any claim against the other party other except for any prior breach of contract.
It is expected to open the first BNCT boron neutron treatment center in Hong Kong, and the Chinese Medicine Service (08037) wants to enter the Hong Kong-Shenzhen Science and Technology Innovation Park
The reason behind the memorandum of understanding with the Hong Kong-Shenzhen Science and Technology Innovation Park is a concrete reflection of China's biotechnology services speeding up the commercialization process of boron neutron capture therapy.
China Biotechnology Services (08037.HK) signs MOU with Hong Kong-Shenzhen Innovation and Technology Park
Gelonghui, April 18, 丨 China Biotechnology Service (08037.HK) announced that the Hong Kong-Shenzhen Innovation and Technology Park Limited (“Hong Kong-Shenzhen Innovation and Technology Park Corporation”) signed a memorandum of understanding with about 60 partner organizations (including companies), and held the Hong Kong-Shenzhen Innovation and Technology Park partner launch ceremony on April 18, 2024. According to the Memorandum of Understanding between the Company and Hong Kong-Shenzhen Innovation and Technology Park Corporation (collectively referred to as the “parties concerned”), the parties concerned have agreed (among others) to cooperate in the development of the Hong Kong-Shenzhen Innovation and Technology Park in the Lok Ma Chau Hetao area of the Hetao Shenzhen-Hong Kong Science and Technology Cooperation Zone. Development of boron neutron capture in cancer treatment
中國生物科技服務：2023 年報
China Biotechnology Services (08037) achieved revenue of approximately HK$212 million in 2023
China Biotechnology Services (08037) announced its 2023 results, with revenue of approximately HK$212 million and gross profit of 343...
CH BIOTECH SER: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
China Biotech Services (08037.HK) plans to place convertible bonds with a total principal amount of up to HK$88 million
Gelonghui, March 26, 丨 China Biotech Service (08037.HK) announced that on March 25, 2024, the company entered into a placement agreement with Guoyuan Finance (Hong Kong) Limited (as placement agent). According to this, the company has appointed an placement agent to distribute convertible bonds with a total principal amount of up to HK$88 million to no less than 6 undertakers. Such undertakers and their ultimate beneficial owners are independent third parties. Based on the initial exchange price of HK$0.55 per share, a maximum of 1.6 will be allotted and issued upon full exercise of the share conversion rights attached to the convertible bonds
CH BIOTECH SER: POSTPONEMENT OF BOARD MEETING
Chinese Medicine Services (08037) and Guanhe Pharmaceutical jointly build a joint laboratory in Hong Kong to carry out CRO services
On March 12, 2024, Guanhe Pharmaceutical and China Biotech Services Holdings Limited reached a strategic cooperation to jointly establish the “Zhongsheng Medical Service-Guanhe Joint Laboratory” in Hong Kong.
China Biotechnology Services (08037.HK) Profit Alert: Expected net loss of HK$90 million for the 2023 fiscal year
On February 28, GLONGHUI | China Biotech Services (08037.HK) announced that for the year ended 31 December 2023 (“Fiscal Year 2023”), the Group is expected to record a net loss attributable to the company owner of approximately HK$90 million in fiscal year 2023. Compared with losses, the Group recorded net profit attributable to company owners of approximately HK$258 million in the same period in 2022. The Board believes that the loss recorded was mainly due to (i) the COVID-19 nuclear impact on the Group due to the relaxation and subsequent cancellation of the COVID-19 quarantine regulations imposed by the relevant government authorities
The world's first boron neutron capture therapy was officially approved. China Biotech Service and Sumitomo Heavy Industries are expected to officially launch BNCT treatment services in Lecheng, Boao this year
Gelonghui, Feb. 28 | The authoritative international journal “Vaccine” published: The world's first boron neutron capture therapy was officially approved. Currently, the only approved products in the world are the “HM-30 Neutron Irradiation System NeuCure” produced by Sumitomo Heavy Industries in Japan and the “Boron Flanged Boron Drug Steboronine” produced by Stella Pharma. According to reports, in June 2022, China Biotechnology Service Holdings (8037.HK) signed a cooperation agreement with Japan's Sumitomo Heavy Industries and Stella Pharma to determine the neutrons produced by Japan's Sumitomo Heavy Industries to be used in this study
China Biotech Services (08037.HK) received 95,000 additional shares of common shares by Liu Xiaolin, worth approximately HK$63,900
On January 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 22, Liu Xiaolin increased his common stock holdings of $China Biotech Services (08037.HK) by $95,000 at an average price of HK$0.6726 per share on January 18, worth about HK$63,900. After the increase in holdings, Liu Xiaolin's latest shareholding was 531 million shares, and the good position ratio rose from 55.07% to 55.08%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies.
China Biotech Services (08037.HK) received 30,000 additional shares of common stock by Liu Xiaolin, worth approximately HK$21,000
On January 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 22, Liu Xiaolin increased his common stock holdings of $China Biotech Services (08037.HK) by $30,000 at an average price of HK$0.7 per share on January 19, worth about HK$21,000. After the increase in holdings, Liu Xiaolin's latest shareholding was 531 million shares, with a good position ratio of 55.08%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies
China Biotech Services (08037.HK) received 95,000 additional shares of common shares by Liu Xiaolin, worth approximately HK$65,000
On January 3, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 3, 2023, Liu Xiaolin increased his share holdings of $China Biotech Services (08037.HK) by $95,000 at an average price of HK$0.6837 per share, worth about HK$65,000. After the increase in holdings, Liu Xiaolin's latest shareholding was 530 million shares, and the good position ratio rose from 55.06% to 55.07%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies
China Biotech Services (08037.HK) received 50,000 additional shares of common stock by Liu Xiaolin, worth approximately HK$354,000
On January 3, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 3, 2023, Liu Xiaolin increased his share holdings of $China Biotech Services (08037.HK) by 50,000 shares at an average price of HK$0.708 per share, worth about HK$354,000. After the increase in holdings, Liu Xiaolin's latest shareholding was 530 million shares, with a good position ratio of 55.07%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and directors of listed companies
China Biotech Services (08037.HK) received 30,000 additional shares of common stock by Liu Xiaolin, worth approximately HK$18,000
On January 3, it was reported that according to the documents disclosed by the Hong Kong Stock Exchange on January 3, 2023, Liu Xiaolin increased his common share holdings of $China Biotech Services (08037.HK) by $30,000 at an average price of HK$0.6 per share, worth about HK$18,000. After the increase in holdings, Liu Xiaolin's latest shareholding was 530 million shares, and the good position ratio rose from 55.05% to 55.06%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Listed companies
China Biotechnology Service (08037.HK): Shanghai Longyao received a strategic investment of 98 million yuan to promote CAR-T cell therapy and other major business growth opportunities for the Group
On December 9, China Biotech Service (08037.HK) issued an announcement. On December 8, 2023, the company, Shanghai Longyao (an indirect non-wholly owned subsidiary of the company) and the investor Yixing Environmental Science Park Equity Investment Partnership (Limited Partnership) entered into a capital injection agreement of RMB 48 million. According to this (i) investors agreed to make a capital injection of RMB 48 million, of which RMB 2,99,670 was used to subscribe for 5.35% of Shanghai Longyao's registered share capital, and RMB 47.01 million into Shanghai Longyao's share capital reserve. ii) Company Agree (Adopted to be completed in China
Shanghai Longyao Biotech completes 100 million yuan financing to focus on CD20 CAR-T phase II clinical trial
This round of financing was led by the Yixing Environmental Science Park Production and Development Equity Investment Partnership (Limited Partnership), and the controlling shareholder, China Biotech Service, continues to increase.
Analysis
Price Target
No Data
